ClinicalTrials.Veeva
Menu

Find clinical trials for Ovarian Cancer in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Montréal, QC, CAN:

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer (IPROC)

This study is being done to answer the following question: What are the effects of a new drug or drugs on ovarian cancer? The pre-s...

Enrolling
Ovarian Cancer
Drug: Durvalumab
Drug: BA3011

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 6 other locations

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 125 other locations

be tested together for the first time in patients with recurrent ovarian, fallopian tube, or peritoneal cancer to determine the saf...

Active, not recruiting
Recurrent Epithelial Ovarian Cancer
Recurrent Peritoneal Cancer
Drug: Epacadostat (INCB024360)
Drug: Cyclophosphamide

Phase 1, Phase 2

Immunovaccine

Montréal, Quebec, Canada and 8 other locations

mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in...

Active, not recruiting
Epithelial Ovarian Cancer
Fallopian Tube Cancer
Drug: Pegylated Liposomal Doxorubicin + SL-172154
Drug: Mirvetuximab + SL-172154

Phase 1

Shattuck Labs

Montréal, Quebec, Canada and 20 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Montréal, Canada and 46 other locations

positive, recurrent platinum sensitive, high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer following 1 pri...

Active, not recruiting
Primary Peritoneal Cancer
High Grade Ovarian Cancer
Drug: Mirvetuximab soravtansine
Drug: Carboplatin

Phase 2

ImmunoGen
ImmunoGen

Montréal, Quebec, Canada and 70 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Montreal, Quebec, Canada and 176 other locations

While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer bec ...

Active, not recruiting
Ovarian Cancer Prevention
Drug: Acetylsalicylic acid
Other: Placebo

Phase 2

Canadian Cancer Trials Group

Montreal, Quebec, Canada and 16 other locations

This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...

Active, not recruiting
Recurrent Ovarian Cancer
Recurrent Primary Peritoneal Carcinoma
Drug: Relacorilant, 100mg QD
Drug: Relacorilant, 150mg QD

Phase 2

Corcept Therapeutics
Corcept Therapeutics

Montréal, Quebec, Canada and 20 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems